Drug-eluting stents or balloon angioplasty for drug-eluting stent-associated restenosis: An observational follow-up study of first-time versus repeated restenosis

Abstract

Background: The treatment of patients with repeated drug-eluting stent–in stent restenosis (DES-ISR) remains a challenge and a burdensome clinical problem. Methods: Over a 3-year period, 130 lesions in 123 patients who underwent target lesion revascularization (TLR) for DES restenosis were included in the study. They were classified into two main groups: the first group having first-time DES-ISR (n = 84), and the second group having rerestenosis of DES-treated DES-ISR (n = 39). Further classification according to the treatment strategy yielded four subgroups: balloon angioplasty (BA) in first-time DES-ISR (n = 66), re-DES in the same group (n = 22), BA in rerestenosis of DES-treated DES-ISR (n = 30), and re-DES in the same group (n = 10). Angiographic follow-up was planned at 1 year, and clinical follow-up for re-TLR up to 2 years later. Results: The mean duration of clinical follow-up was 24.8 ± 9.7 months. The angiographic follow-up data were obtained for 108 patients (87.8%) at 1 year. Among patients treated for first-time DES-ISR, late lumen loss (0.65 ± 0.83 mm and 1.02 ± 0.52 mm, p = 0.02) and binary restenosis rates (25% and 49.1%, p = 0.05) were significantly less in those undergoing re-DES compared with BA. This benefit was not evident in patients having rerestenosis of DES-treated DES-ISR. Re-TLR at 2 years was significantly less in the re-DES group compared with BA (log rank p = 0.038) in first-time DES-ISR patients, while no significant difference (log rank p = 0.58) was observed in those having rerestenosis of DES-treated DES-ISR. Conclusion: While a strategy of re-DES would be better than BA in first-time DES-ISR, this could not be extrapolated to rerestenosis cases.

Keywords

• Balloon angioplasty
• Drug-eluting stents
• In-stent restenosis
• Rerestenosis